Comparable stake leader
BlackRock, Inc.
SEC ownership of COLLEGIUM PHARMACEUTICAL, INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001267565.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
17 Aug 2026
- Public ticker
- COLL on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
17 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001267565
- Issuer location
- Stoughton, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of COLLEGIUM PHARMACEUTICAL, INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
17 Aug 2026
13F
13D/G
3/4/5
Lead comparable stake: 16%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 16%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
16%
Janus Henderson Group Ltd.
5.8%
INTEGRATED CORE STRATEGIES (US) LLC
5.6%
FULLER & THALER ASSET MANAGEMENT,...
5%
VANGUARD CAPITAL MANAGEMENT LLC
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
16%
from 13D/G
|
$196,971,512
5,441,202 shares
|
— | 30 Jun 2026 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
5.8%
|
$60,374,279
1,825,651 shares
|
$0 | 31 Mar 2026 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
Millennium Management LLC
|
5.6%
|
$64,785,545
1,820,330 shares
|
+$10,706,540 | 17 Aug 2026 |
| FULLER & THALER ASSET MANAGEMENT, INC. |
13F
13D/G
Company
|
5%
from 13D/G
|
$59,106,662
1,632,781 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5%
|
$58,253,166
1,625,821 shares
|
$0 | 30 Jun 2026 |
| Invesco Ltd. |
13F
13D/G
Company
|
5%
from 13D/G
|
$68,146,464
1,882,499 shares
|
— | 30 Jun 2026 |
| PRINCIPAL GLOBAL INVESTORS |
13D/G
|
5%
|
$58,487,459
1,632,360 shares
|
+$5,942,549 | 30 Jun 2026 |
| Rubric Capital Management LP |
3/4/5
13D/G
13F
10%+ Owner · Company
|
4.7%
from 13D/G
|
$118,574,322
3,132,743 shares
|
— | 13 Aug 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$7,916,619.
Buys
$0
Insiders: 0
Sells
$7,916,619
Insiders: 9
Net
-$7,916,619
Shares: -191,104
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 191,104
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 87,523 | $0 | $3,364,225 | -$3,364,225 |
| 6-9 | 0 | 21,250 | $0 | $1,019,529 | -$1,019,529 |
| 9-12 | 0 | 82,331 | $0 | $3,532,865 | -$3,532,865 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 21 reporting-owner rows connected to COLLEGIUM PHARMACEUTICAL, INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
21
Largest Forms 3/4/5 holder
Rubric Capital Management LP
Net 12M change
-$7,916,619
Latest report
08 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Rubric Capital Management LP | 10%+ Owner | $118,574,322 | Filing P/S | 13 Aug 2025 | ||
| Joseph Ciaffoni | President and CEO, Director | $14,992,018 | Mixed | 12 Feb 2024 | ||
| Vikram Karnani | President and CEO, Director | $9,250,142 | Mixed | 10 Feb 2026 | ||
| Colleen Tupper | EVP & Chief Financial Officer | $6,885,433 | -$1,215,753 | -15% | Mixed | 10 Feb 2026 |
| Alison B. Fleming | EVP & Chief Technical Officer | $4,638,457 | Mixed | 10 Aug 2021 | ||
| Thomas B. Smith MD | EVP and Chief Medical Officer | $4,237,934 | -$671,576 | -14% | Mixed | 10 Feb 2026 |
| Richard Malamut | EVP and Chief Medical Officer | $4,204,935 | Mixed | 10 Feb 2022 | ||
| John G. Freund | Director | $3,908,669 | -$143,228 | -3.5% | Mixed | 18 May 2026 |
| Gino Santini | Director | $3,719,812 | Mixed | 08 Jun 2026 | ||
| Shirley R. Kuhlmann | EVP and General Counsel | $3,082,056 | Filing P/S | 04 Mar 2025 | ||
| John A. Fallon MD | Director | $3,051,603 | -$1,645,536 | -35% | Filing P/S | 12 Nov 2025 |
| Scott Dreyer | EVP & Chief Commercial Officer | $2,941,773 | -$2,867,292 | -49% | Filing P/S | 03 Mar 2026 |
| David Dieter | EVP & General Counsel | $2,691,635 | -$716,209 | -21% | Filing P/S | 18 Mar 2026 |
| Garen G. Bohlin | Director | $2,347,970 | -$323,491 | -12% | Mixed | 14 May 2026 |
| Rita J. Balice-Gordon | Director | $2,029,505 | -$171,673 | -7.8% | Mixed | 14 May 2026 |
| Gwen A. Melincoff | Director | $1,694,890 | Mixed | 16 May 2024 | ||
| Neil F. McFarlane | Director | $1,594,652 | Mixed | 16 May 2024 | ||
| Michael Thomas Heffernan | Director | $1,536,011 | Mixed | 10 Feb 2025 | ||
| Carlos Paya V | Director | $936,641 | Mixed | 14 May 2026 | ||
| Nancy Lurker | Director | $884,887 | -$161,861 | -15% | Mixed | 14 May 2026 |
Recent insider transactions for COLLEGIUM PHARMACEUTICAL, INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Gino Santini | COLL | Common Stock | Options Exercise | 8.38% | 8,700 | 112,483 | 08 Jun 2026 | Direct | ||
| Gino Santini | COLL | Stock Option (Right to Purchase) | Options Exercise | -100% | -8,700 | 0 | 08 Jun 2026 | Direct | ||
| John G. Freund MD | COLL | Common Stock | Sale | -0.02% | $681 | $34.05 | -20 | 83,952 | 18 May 2026 | Direct |
| John G. Freund MD | COLL | Common Stock | Sale | -4.68% | $142,547 | $34.54 | -4,127 | 83,972 | 15 May 2026 | Direct |
| John G. Freund MD | COLL | Common Stock | Options Exercise | 11% | 8,700 | 88,099 | 15 May 2026 | Direct | ||
| John G. Freund MD | COLL | Stock Option (Right to Purchase) | Options Exercise | -100% | -8,700 | 0 | 15 May 2026 | Direct | ||
| Nancy Lurker | COLL | Common Stock | Award | 48.5% | 8,741 | 26,758 | 14 May 2026 | Direct | ||
| Carlos V Paya MD | COLL | Common Stock | Award | 44.6% | 8,741 | 28,323 | 14 May 2026 | Direct | ||
| John G. Freund MD | COLL | Common Stock | Award | 12.4% | 8,741 | 79,399 | 14 May 2026 | Direct | ||
| Donovan Michael Glancy | COLL | Common Stock | Award | 17,482 | 17,482 | 14 May 2026 | Direct | |||
| Garen G. Bohlin | COLL | Common Stock | Award | 14% | 8,741 | 71,000 | 14 May 2026 | Direct | ||
| Rita J. Balice-Gordon | COLL | Common Stock | Award | 16.6% | 8,741 | 61,370 | 14 May 2026 | Direct | ||
| Gino Santini | COLL | Common Stock | Award | 9.2% | 8,741 | 103,783 | 14 May 2026 | Direct | ||
| Nancy Lurker | COLL | Common Stock | Sale | -20% | $161,861 | $35.97 | -4,500 | 18,017 | 13 May 2026 | Direct |
| Garen G. Bohlin | COLL | Common Stock | Sale | -12.3% | $323,491 | $37.18 | -8,700 | 62,259 | 11 May 2026 | Direct |
| Garen G. Bohlin | COLL | Common Stock | Options Exercise | 14% | 8,700 | 70,959 | 11 May 2026 | Direct | ||
| Garen G. Bohlin | COLL | Stock Option (Right to Purchase) | Options Exercise | -100% | -8,700 | 0 | 11 May 2026 | Direct | ||
| David Dieter | COLL | Common Stock | Sale | -15.4% | $488,099 | $34.92 | -13,976 | 77,071 | 18 Mar 2026 | Direct |
| David Dieter | COLL | Common Stock | Tax liability | -11.5% | -8,840 | 68,231 | 17 Mar 2026 | Direct | ||
| David Dieter | COLL | Common Stock | Sale | -6.4% | $228,110 | $36.65 | -6,224 | 91,047 | 09 Mar 2026 | Direct |
| Scott Dreyer | COLL | Common Stock | Sale | -41% | $2,019,437 | $40.41 | -49,976 | 71,770 | 03 Mar 2026 | Direct |
| David Dieter | COLL | Common Stock | Tax liability | -2.78% | -2,781 | 97,271 | 10 Feb 2026 | Direct | ||
| David Dieter | COLL | Common Stock | Award | 45.3% | 31,199 | 100,052 | 10 Feb 2026 | Direct | ||
| Vikram Karnani | COLL | Common Stock | Tax liability | -5.4% | -11,296 | 197,864 | 10 Feb 2026 | Direct | ||
| Vikram Karnani | COLL | Common Stock | Award | 114.8% | 111,795 | 209,160 | 10 Feb 2026 | Direct | ||
| Thomas B. Smith MD | COLL | Common Stock | Tax liability | -16.1% | -17,435 | 90,651 | 10 Feb 2026 | Direct | ||
| Thomas B. Smith MD | COLL | Common Stock | Award | 52.1% | 37,042 | 108,086 | 10 Feb 2026 | Direct | ||
| Colleen Tupper | COLL | Common Stock | Tax liability | -20.7% | -38,540 | 147,282 | 10 Feb 2026 | Direct | ||
| Colleen Tupper | COLL | Common Stock | Award | 46.7% | 59,155 | 185,822 | 10 Feb 2026 | Direct | ||
| Scott Dreyer | COLL | Common Stock | Tax liability | -20.6% | -31,592 | 121,746 | 10 Feb 2026 | Direct | ||
| Scott Dreyer | COLL | Common Stock | Award | 48% | 49,725 | 153,338 | 10 Feb 2026 | Direct | ||
| Scott Dreyer | COLL | Common Stock | Sale | -14.5% | $847,855 | $48.17 | -17,600 | 103,613 | 08 Dec 2025 | Direct |
| Scott Dreyer | COLL | Common Stock | Options Exercise | 17% | 17,600 | 121,213 | 08 Dec 2025 | Direct | ||
| Scott Dreyer | COLL | Stock Option (Right to Purchase) | Options Exercise | -100% | -17,600 | 0 | 08 Dec 2025 | Direct | ||
| Rita J. Balice-Gordon | COLL | Common Stock | Sale | -6.49% | $171,673 | $47.03 | -3,650 | 52,629 | 05 Dec 2025 | Direct |
| Vikram Karnani | COLL | Common Stock | Tax liability | -8.48% | -8,983 | 96,989 | 12 Nov 2025 | Direct | ||
| John A. Fallon MD | COLL | Common Stock | Sale | -35% | $1,645,536 | $47.21 | -34,853 | 64,634 | 12 Nov 2025 | Direct |
| John A. Fallon MD | COLL | Common Stock | Options Exercise | 53.9% | 34,853 | 99,487 | 12 Nov 2025 | Direct | ||
| John A. Fallon MD | COLL | Stock Option (Right to Purchase) | Options Exercise | -100% | -34,853 | 0 | 12 Nov 2025 | Direct | ||
| Colleen Tupper | COLL | Common Stock | Sale | -19.2% | $1,215,753 | $40.53 | -30,000 | 126,667 | 06 Nov 2025 | Direct |
| Thomas B. Smith MD | COLL | Common Stock | Sale | -19.9% | $671,576 | $38.42 | -17,478 | 70,264 | 29 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.